HCPCS Level II code J9292 denotes a 10 mg injectable unit of pemetrexed dipotassium, an antineoplastic agent commonly used in chemotherapy regimens. The code is important nationwide because it standardizes billing for a high-cost specialty oncology drug administered by infusion, facilitating claims processing, coverage decisions, and price benchmarking across payers. Key payers considered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for pemetrexed administration, expected sites of service (hospital outpatient infusion centers and physician office infusion suites), and the types of benchmarks and policy elements typically relevant to this HCPCS Level II code. The publication summarizes reimbursement benchmarks, common billing practices, and payer policy considerations that affect coverage and prior authorization. It also outlines areas where policy updates and coding guidance are commonly applied for injectable oncology drugs. Data not available in the input is noted where specific payer rates, associated taxonomies, ICD-10 pairings, and related codes would normally be presented.